A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Phase 3 Completed 747 enrolled Shanghai Junshi Bioscience Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of JS005 in 702 adult patients with moderate-to-severe chronic plaque psoriasis

Timeline

Start: 2023-08-28
Primary completion: 2025-08-20
Completion: 2025-09-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ROCONKIBART	Monoclonal antibody	150 mg	Subcutaneous
Subject	ROCONKIBART	Monoclonal antibody	300 mg	Subcutaneous

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Summary

Timeline

Drugs

Indications